Actavis gets $70B-plus in orders for new bond offering; Salix sales plummet after inventory snafu;

@FiercePharma: IYCMI yesterday: Medicare urged to crack down on antipsychotic scripts for dementia sufferers. Report | Follow @FiercePharma

@EricPFierce: FDA unloads another 14 observations on Hospira Vizag India plant, further delaying its opening. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: To avoid becoming deal bait, Mylan CEO may have to make another big buy. News | Follow @CarlyHFierce

> Actavis' ($ACT) new bond offering is a hot prospect, with orders reportedly reaching $70 billion to $90 billion for an intended sale of $22 billion; proceeds will be used to help fund the company's $66 billion Allergan buyout. Report

> Salix Pharmaceuticals ($SLXP), set to be acquired by Valeant, posted a fourth-quarter loss on a steep decline in revenue, to $13 million from $238 million the prior year; the loss was expected after the company announced a previously unreported and large buildup in inventory at the wholesale level. Report

> At its Wednesday annual meeting, Roche ($RHHBY) added two new board members, the former CEO of Wyeth, Bernard Poussot, and Yale University genomics professor Richard Lifton. Release

> Two members of Congress have joined other government officials challenging Amphastar Pharmaceuticals on its rising price for the overdose-fighting drug naloxone. Report

> France-based Ipsen posted 2014 sales of €1.27 billion ($1.42 billion), a 6% increase, which fueled an 8.6% increase in profits, to €154.5 million. Report

> Sanofi's ($SNY) animal health company Merial wrapped up its purchase of two horse products, the joint injection Legend and neurological treatment Marquis, from Bayer HealthCare. Report

Medical Device News

@FierceMedDev: UPDATED with interview: FDA approves Actavis intrauterine device to prevent pregnancy. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Boston Sci to acquire Endo's men's health devices for $1.6B. Story | Follow @VarunSaxena2

> Nevro appoints former JJDC head to board as it awaits anticipated FDA approval. More

> In loss for Medtronic, appeals court overturns $102M owed by NuVasive for patent infringement. Story

> Siemens Healthcare accused of faking contracts in China. Report

Biotech News

@FierceBiotech: Bullish ex-Elan chief plots a $43M buy-in for upstart Serenus. Article | Follow @FierceBiotech

@JohnCFierce: Remember when the NVCA wailed over the unsustainable VC model in biotech, the FDA's fossilized review process? Ah, the old days... in 2012. | Follow @JohnCFierce

@DamianFierce: German Merck refers to itself as "Merck KGaA, Darmstadt, Germany" on every reference. We get it. You're German. More | Follow @DamianFierce

> Boehringer takes pole position with its 'breakthrough' anti-anticoagulant. Article

> Ambitious cancer R&D plans may explain Merck KGaA cutbacks. Item

> J&J picks the inaugural class for its Bay Area biotech incubator. Report

Biotech Research News

> Canadian researchers study a new mechanism of action for cancer metastasis. More

> Scripps investigators ID a key player in disarming chemotherapy. Report

> Glioblastoma project IDs a new approach to brain cancer and understanding EGFR. Article

> Researchers add insights to IL-37's anti-inflammatory potential. More

> Mount Sinai preclinical program flags a potential drug strategy for MS. Story

Pharma Manufacturing News

> Hospitals say Roche supply chain move is affecting patient care. Item

> Pfizer shuttering vitamin C plant in California, 70 workers out of jobs. Report

> Hospira's new India plant again faulted by the FDA. Story

> Companies strike trans-Pacific manufacturing and development agreement. More

> G&W Laboratories buying Teva plant after picking up one from Actavis. Article

Pharma Asia News

> Sun Pharma buys GSK's Tasmania opiates business to expand pain offerings. More

> Gilead moves from Japan to India lining up hep C, HIV licensing deals. Story

> Singapore's TauRx notes Alzheimer's candidate journal publication, but buzz eludes. Article

> Takeda confirms eyeing opportunities in India, elsewhere, in vaccine space. News

> Deadly flu outbreak in Hong Kong gathers pace, prompting vaccination push. More

And Finally... Most doctors give in to requests by parents to avoid or delay vaccinations, a survey found. Report

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."